Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin add-on to sildenafil for erectile dysfunction with inadequate response to PDE5 inhibitor therapy
2021-005496-39Phase 3Completed
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in erectile dysfunction (ED) comparing Xeomin + sildenafil with Placebo + sildenafil (2 arms). Primary endpoint: Change in International Index of Erectile Function - Erectile Function domain score. Started Oct 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on 2021-005496-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005496-39.